Pipeline

Our pipeline of antibody therapeutics includes in-house and partnered pre-clinical programs

Name
Antibody
Development
PoC
Studies
Preclinial
Phase 1
GT-001
(Lewis-Y)
Antibody
Development
PoC
Studies
Preclinial
Phase 1
GT-002
(undisclosed)
Antibody
Development
PoC
Studies
Preclinial
Phase 1
Additional Targets
(undisclosed)
Antibody
Development
PoC
Studies
Preclinial
Phase 1
GT-00A x IL15
(TA-MUC1 x IL-15)
Antibody
Development
PoC
Studies
Preclinial
Phase 1
GT-00A ADC
(TA-MUC1 x Toxin)
Antibody
Development
PoC
Studies
Preclinial
Phase 1
Daiichi-Logo
GT-00A CAR-T
(TA-MUC1)
Antibody
Development
PoC
Studies
Preclinial
Phase 1
Partner
Undisclosed
GT-00A CAR-NK
(TA-MUC1)
Antibody
Development
PoC
Studies
Preclinial
Phase 1
ONK Therapeutics Logo

GT-001 is a humanized IgG1 mAb with unrivaled fine-specificity, specifically targeting the tumor-associated Lewis Y (LeY, CD174) carbohydrate antigen without cross-reactivity to related carbohydrates expressed on blood cells. GT-001 binds to a high percentage of breast cancers non-small cell lung cancer, colorectal cancer, head and neck cancer, small cell lung cancer and ovarian cancer patient samples and is effectively internalized, making it suitable for ADC or CAR development.

GT-00A is a humanized IgG1 mAb targeting tumor-associated (TA)-MUC1. GT-00A is in pre-clinical development as an IL-15-based immuno-cytokine, as ADC and as CAR-T and CAR-NK in the field of cellular therapies. TA-MUC1 is a novel tumor-specific protein/carbohydrate combined glyco-epitope on the tumor-marker MUC1. The target is expressed on many epithelial tumor types including primary tumor, metastases and cancer stem cells, but is virtually absent on normal cells. Main target indications are ovarian, lung, breast, further potential for treatment of cervical, endometrial, gastrointestinal, kidney, urothelial and other cancers.

GT-00A based IL-15 immuno-cytokine: Cytokines have long been used for cancer therapy to activate the immune system, but side effects and short half-life limit their therapeutic application. The concept of tumor-specific targeting to the tumor microenvironment to use the full potential of IL-15 biology is unique within the competitive field of IL-15 (super)agonists. Our immune-cytokine attracts and activates immune cells (e.g. T and NK cells) directly at the tumor site thereby turning an “immune desert” into a “hot” tumor and inducing tumor cell lysis. A comprehensive non-clinical data package is available and the First in Human study is planned for early 2023. We are now actively looking for a partner for co-development/out-licensing.